Effect of melatonin administration on the PER1 and BMAL1 clock genes in patients with Parkinson's disease

Biomed Pharmacother. 2020 Sep:129:110485. doi: 10.1016/j.biopha.2020.110485. Epub 2020 Jul 6.

Abstract

Sleep disorders are a widespread condition in patients with Parkinson's disease (PD), which has been linked to a deregulation of the circadian cycle and therefore of the clock genes. The aim of this study was to evaluate the effect of melatonin (MEL) on the PER1 and BMAL1 clock genes in patients with PD. A double-blind, cross-over, placebo-controlled randomized clinical trial pilot study was conducted in 26 patients with stage 1-3 PD according to the Hoehn & Yahr scale, who received either 25 mg of MEL or a placebo at noon and 30 min before bedtime for three months. The relative expression of the PER1 and BMAL1 genes was measured, as well as the presence of daytime, nocturnal, and global sleepiness, and the progression of PD. The levels of the PER1 and BMAL1 genes at baseline were 0.9 (0.1-3) vs. 0.56 (0.1-2.5), respectively; while after the intervention with MEL or placebo the BMAL1 levels increased to 2.5 (0-3.70) vs. 2.2 (0.10-3.30), respectively (d = 0.387). Fifty percent (50 %) of patients had daytime sleepiness and sixty-five percent (65 %) had abnormal nighttime sleepiness, yet neither group showed changes after the intervention. Patients with PD exhibited an alteration in the levels of the clock genes: MEL increased the levels of BMAL1, but the PER1 levels remained unchanged.

Keywords: BMAL1gene; Clock genes; Melatonin; PER1gene; Parkinson's disease.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • ARNTL Transcription Factors / blood
  • ARNTL Transcription Factors / genetics*
  • Adult
  • Aged
  • Cross-Over Studies
  • Double-Blind Method
  • Female
  • Gene Expression Regulation
  • Humans
  • Male
  • Melatonin / administration & dosage*
  • Mexico
  • Middle Aged
  • Parkinson Disease / blood
  • Parkinson Disease / diagnosis
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / genetics
  • Period Circadian Proteins / blood
  • Period Circadian Proteins / genetics*
  • Pilot Projects
  • Sleep Wake Disorders / blood
  • Sleep Wake Disorders / diagnosis
  • Sleep Wake Disorders / drug therapy*
  • Sleep Wake Disorders / genetics
  • Time Factors
  • Treatment Outcome

Substances

  • ARNTL Transcription Factors
  • BMAL1 protein, human
  • PER1 protein, human
  • Period Circadian Proteins
  • Melatonin